ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Methyldopa: Drug information

Methyldopa: Drug information
(For additional information see "Methyldopa: Patient drug information" and see "Methyldopa: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Pharmacologic Category
  • Alpha2-Adrenergic Agonist;
  • Antihypertensive
Dosing: Adult
Hypertension

Hypertension (alternative agent):

Oral: Initial: 250 mg 2 to 3 times daily; titrate daily dose at least every 2 days based on response; usual dose range: 250 mg to 1 g daily in 2 to 4 divided doses; maximum dose: 3 g/day in divided doses (Ref). Note: When administered with other antihypertensives other than thiazide diuretics, limit initial daily dose of methyldopa to 500 mg/day in divided doses.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (Ref):

CrCl >50 mL/minute: Administer every 8 hours.

CrCl 10 to 50 mL/minute: Administer every 8 to 12 hours.

CrCl <10 mL/minute: Administer every 12 to 24 hours.

Intermittent hemodialysis: Moderately dialyzable (up to 60% with a 6-hour session): Administer after hemodialysis on dialysis days (Ref).

Peritoneal dialysis (PD): Administer every 12 to 24 hours.

Continuous renal replacement therapy (CRRT): Administer every 8 to 12 hours. Note: Use of antihypertensives in patients requiring CRRT is generally not recommended since CRRT is typically employed when patient cannot tolerate intermittent hemodialysis due to hypotension.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; use is contraindicated in patients with active hepatic disease.

Dosing: Older Adult

Avoid use (Ref).

Dosing: Pediatric

(For additional information see "Methyldopa: Pediatric drug information")

Hypertension

Hypertension: Note: Use has been replaced by other agents; methyldopa not suggested as a treatment option for hypertension (Ref).

Children and Adolescents: Oral: Initial: 10 mg/kg/day in 2 to 4 divided doses; titrate no more frequently than every 2 days until adequate response to maximum daily dose: 65 mg/kg/day or 3,000 mg/day, whichever is less (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; based on experience in adult patients, dosing adjustment suggested.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; use is contraindicated in patients with active hepatic disease.

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified.

Postmarketing:

Cardiovascular: Bradycardia, edema, exacerbation of angina pectoris, heart failure, myocarditis (Webster 1996), orthostatic hypotension (Paykel 1982), pericarditis, prolonged carotid sinus syncope (Bauernfeind 1978), vasculitis (Matteson 1989)

Dermatologic: Lichenoid eruption (Holt 1974), skin rash (including eczema, papular rash, seborrheic dermatitis, and urticaria) (Gidseg 1986, Holt 1974), toxic epidermal necrolysis

Endocrine & metabolic: Amenorrhea (Arze 1981), decreased libido (Newman 1974), gynecomastia (Caldwell 1981), hyperprolactinemia (Arze 1981), weight gain (Caldwell 1981)

Gastrointestinal: Abdominal distention, cholestasis, colitis, constipation, diarrhea (Caldwell 1981), flatulence, glossalgia, melanoglossia, nausea (Caldwell 1981), pancreatitis (Van der Heide 1981), sialadenitis, vomiting, xerostomia (Caldwell 1981)

Genitourinary: Breast hypertrophy (Pettinger 1964), impotence (Caldwell 1981), lactation (Pettinger 1964), nocturia (Caldwell 1981)

Hematologic & oncologic: Bone marrow depression, eosinophilia, granulocytopenia, hemolytic anemia (including autoimmune hemolytic anemia) (Böttiger 1973, Surveyor 1968), leukopenia, neutropenia (Greene 1967), positive ANA titer (Dupont 1982), positive direct Coombs test (Dupont 1982), thrombocytopenia

Hepatic: Abnormal hepatic function tests (Shashaty 1979), cholestatic hepatitis (Toghill 1974), cholestatic jaundice (Hoffbrand 1974), hepatic cirrhosis (Shashaty 1979), hepatic necrosis (Toghill 1974), hepatitis (Thomas 1997), hepatocellular hepatitis, hepatotoxicity (Toghill 1974), jaundice (Toghill 1974)

Nervous system: Asthenia, Bell palsy, cerebrovascular insufficiency (symptoms), decreased mental acuity (Paykel 1982), depression (Caldwell 1981), dizziness (Caldwell 1981), drowsiness (Caldwell 1981), drug fever (Kumar 1986), fatigue (Caldwell 1981), headache (Caldwell 1981), involuntary choreoathetoid movements (Neil 1981), paresthesia (Caldwell 1981), parkinsonism (Strang 1966), psychic disorder (including nightmares, psychosis) (Webster 1996), sedated state (Paykel 1982), sleep disturbance (including insomnia and nightmares) (Paykel 1982)

Neuromuscular & skeletal: Arthralgia, lupus-like syndrome (Dupont 1982), myalgia, positive rheumatoid factor

Renal: Increased blood urea nitrogen

Respiratory: Nasal congestion (Caldwell 1981)

Miscellaneous: Fever, positive LE cell preparation (Harth 1968)

Contraindications

Hypersensitivity to methyldopa or any component of the formulation; active hepatic disease (eg, acute hepatitis, active cirrhosis); hepatic disorders previously associated with use of methyldopa; concurrent use of MAO inhibitors.

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Warnings/Precautions

Concerns related to adverse effects:

• Edema: May produce clinical edema or weight gain; discontinue if edema worsens or signs of heart failure arise. Mild edema may be controlled with the concomitant use of diuretic therapy.

• Hematologic effects: Rare cases of reversible granulocytopenia and thrombocytopenia have been reported. May rarely produce hemolytic anemia; positive Coombs test occurs in 10% to 20% of patients usually occurring between 6 and 12 months of therapy; perform complete blood count (CBC) periodically. If methyldopa-induced Coombs-positive hemolytic anemia occurs during therapy, discontinue use and do not reinitiate; Coombs test may not revert back to normal for weeks to months following discontinuation.

• Hepatic effects: May rarely produce hepatic disorders including fatal hepatic necrosis. Discontinue use and do not reinitiate if fever, abnormal liver function tests, or jaundice is present.

• Sedation: Usually transient, sedation may occur with initiation or whenever the dose is increased.

Disease-related concerns:

• Cerebrovascular disease: Patients with severe bilateral cerebrovascular disease have exhibited involuntary choreoathetotic movements (rare); discontinue use if these symptoms develop.

• Hepatic impairment: Use with caution in patients with history of hepatic disease or impairment.

• Pheochromocytoma: Not recommended in patients with pheochromocytoma.

• Renal impairment: Use with caution in patients with renal impairment; may respond to smaller doses. The active metabolites of methyldopa accumulate in patients with renal impairment.

Special populations:

• Surgical patients: Patients on methyldopa may need less anesthetic agents (Miller 1968; Miller 2010).

Other warnings/precautions:

• Tolerance: May occur usually between the second and third month of therapy; adding a diuretic or increasing the dosage of methyldopa frequently restores blood pressure control.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 250 mg, 500 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Methyldopa Oral)

250 mg (per each): $9.00

500 mg (per each): $12.00

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 125 mg, 250 mg, 500 mg

Administration: Adult

Oral: Administer new dosage increases in the evening to minimize sedation.

Administration: Pediatric

Oral: May be administered without regard to food; administer new dosage increases in the evening to minimize sedation.

Use: Labeled Indications

Hypertension: Management of hypertension. Note: Not recommended for the initial treatment of hypertension (ACC/AHA [Whelton 2018]).

Medication Safety Issues
Sound-alike/look-alike issues:

Methyldopa may be confused with L-dopa, levodopa

Older Adult: High-Risk Medication:

Beers Criteria: Central alpha-agonists (methyldopa) are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older (independent of diagnosis or condition) due to high risk of CNS adverse effects and risk of bradycardia and orthostatic hypotension associated with central alpha blockers; not recommended as routine treatment for hypertension (Beers Criteria [AGS 2023]).

International issues:

Aldomet [Multiple international markets] may be confused with Aldactone brand name for spironolactone [US, Canada, multiple international markets]

Metabolism/Transport Effects

Substrate of COMT

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine. Risk D: Consider therapy modification

Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor therapy

Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable. Risk D: Consider therapy modification

Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Risk X: Avoid combination

COMT Inhibitors: May increase the serum concentration of COMT Substrates. Risk C: Monitor therapy

Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents. Risk C: Monitor therapy

Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. Risk C: Monitor therapy

Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents. Risk C: Monitor therapy

Haloperidol: May enhance the adverse/toxic effect of Methyldopa. Risk C: Monitor therapy

Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. Risk C: Monitor therapy

Indoramin: May enhance the hypotensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Iobenguane Radiopharmaceutical Products: Methyldopa may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer methyldopa until at least 7 days after each iobenguane dose. Risk X: Avoid combination

Iron Preparations: May decrease the serum concentration of Methyldopa. Management: Consider separating doses of methyldopa and orally administered iron preparation by 2 or more hours. Monitor for decreased efficacy of methyldopa if an oral iron preparation is initiated/dose increase, or increased efficacy if discontinued/dose decreased. Risk D: Consider therapy modification

Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. Risk C: Monitor therapy

Lithium: Methyldopa may enhance the adverse/toxic effect of Lithium. This may occur without notable changes in serum lithium concentrations. Risk C: Monitor therapy

Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Mirtazapine: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use. If the combination cannot be avoided, monitor for decreased effects of alpha2-agonists if mirtazapine is initiated/dose increased, or increased effects if mirtazapine is discontinued/dose decreased. Risk D: Consider therapy modification

Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Methyldopa. Risk X: Avoid combination

Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Methyldopa. Management: Consider separating doses of these products by more than 2 hours to minimize this interaction; however, the success of this action appears limited. Monitor for decreased therapeutic effects of methyldopa with concurrent use. Risk D: Consider therapy modification

Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. Risk C: Monitor therapy

Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Risk D: Consider therapy modification

Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. Risk C: Monitor therapy

Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. Risk C: Monitor therapy

Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Riluzole: Methyldopa may enhance the adverse/toxic effect of Riluzole. Specifically, the risk of hepatotoxicity may be increased. Management: Consider alternatives to methyldopa in patients receiving treatment with riluzole due to the potential for additive hepatotoxicity. Risk D: Consider therapy modification

Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the therapeutic effect of Alpha2-Agonists. Risk C: Monitor therapy

Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. Risk C: Monitor therapy

Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding this combination. If used, monitor for decreased effects of the alpha2-agonist. Exercise great caution if discontinuing an alpha2-agonist in a patient receiving a TCA. Risk D: Consider therapy modification

Triptorelin: Hyperprolactinemic Agents may diminish the therapeutic effect of Triptorelin. Risk X: Avoid combination

Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. Risk C: Monitor therapy

Vasopressin: Drugs Suspected of Causing SIADH may enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. Risk C: Monitor therapy

Reproductive Considerations

Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to become pregnant. Methyldopa is an option patients can be transitioned to when one of the preferred agents cannot be used (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).

Pregnancy Considerations

Methyldopa crosses the placenta.

Available data show use during pregnancy does not cause fetal harm and improves fetal outcomes.

Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).

Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). If treatment for chronic hypertension during pregnancy is needed, oral methyldopa is an option; however, other agents may be preferred due to adverse events and decreased effectiveness when compared to other medications (ACOG 2019; ESC [Cífková 2020]; SOGC [Magee 2022]).

Breastfeeding Considerations

Methyldopa is present in breast milk.

Data related to the presence of methyldopa in breast milk are available from multiple reports:

• Breast milk was sampled 30 to 60 minutes following delivery in 4 patients taking methyldopa for at least 4 weeks. The highest breast milk concentrations were obtained in 1 patient taking methyldopa 500 mg every 6 hours. Twelve hours after the last dose, free and conjugated concentrations of methyldopa were 0.2 mcg/mL and 0.9 mcg/mL, respectively (Jones 1978).

• Data related to the presence of methyldopa in breast milk are available from a study of 3 patients. The highest breast milk concentration of free methyldopa (1.14 mcg/mL) was observed in 1 patient 8 weeks postpartum taking methyldopa 1,000 mg/day. In this patient, free methyldopa was ~37% of the total methyldopa (free + conjugate) present in breast milk; methyldopa was detected in the breastfed infant's serum. Using data from all 3 patients, peak breast milk concentrations occurred 3 to 6 hours after the maternal dose. Adverse events were not observed in the breastfed infants (White 1985).

• Methyldopa was also detected in the urine of a breastfed infant. Methyldopa 250 mg twice daily for 10 days was initiated 11 days postpartum to a patient following delivery at 38 weeks gestation. Adverse events were not observed in the infant (Hauser 1985).

• Using a milk concentration of 1.14 mcg/mL, the estimated daily infant dose of methyldopa via breast milk is 0.1716 mg/kg/day providing a relative infant dose (RID) of 1.2% compared to a weight adjusted maternal dose of 1,000 mg/day.

• In general, breastfeeding is considered acceptable when the RID of a medication is <10% (Anderson 2016; Ito 2000).

Methyldopa is compatible with breastfeeding (ESC [Cífková 2020]; SOGC [Magee 2022]; WHO 2002). However, because maternal depression has been reported following methyldopa administration, use of methyldopa should be avoided in the postnatal period due to the underlying risk of depression already present in this patient population (ACOG 2019; Regitz-Zagrosek [ESC 2018]).

Dietary Considerations

Dietary requirements for vitamin B12 and folate may be increased with high doses of methyldopa.

Monitoring Parameters

Blood pressure; CBC; liver enzymes (periodically during the first 6 to 12 weeks or when unexplained fever occurs); Coombs test (direct) (may obtain prior to initiation and at 6 and 12 months).

Mechanism of Action

Stimulation of central alpha-adrenergic receptors by a false neurotransmitter (alpha-methylnorepinephrine) that results in a decreased sympathetic outflow to the heart, kidneys, and peripheral vasculature

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Peak effect: Hypotensive: Single-dose: Within 3 to 6 hours; Multiple-dose: 48 to 72 hours.

Duration: Single-dose: 12 to 24 hours, Multiple-dose: 24 to 48 hours.

Absorption: Incomplete due to presystemic gut metabolism (Skerjanec 1995).

Distribution: Vd: 0.23 L/kg (Myhre 1982).

Protein binding: 10% to 15% (Myhre 1982).

Metabolism: Intestinal and hepatic.

Bioavailability: ~42% (Skerjanec 1995).

Half-life elimination: Neonates: 10 to 20 hours; Adults: 1.5 to 2 hours; End-stage renal disease: Prolonged (Myhre 1982).

Time to peak, plasma: 2 to 4 hours (Myhre 1982).

Excretion: Urine (~70% as parent drug and metabolites); excretion complete within 36 hours.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Aldomet | Dopamat | Hypolag;
  • (AR) Argentina: Aldomet | Dopagrand | Dopatral | Hipermet | Metildopa;
  • (AT) Austria: Aldometil;
  • (AU) Australia: Aldomet | Aldopren | Hydopa;
  • (BD) Bangladesh: Alphamet | Dopamet | Dopegyt | Fidopa | Sardopa;
  • (BE) Belgium: Aldomet | Presinol;
  • (BG) Bulgaria: Aldomet | Dopegyt;
  • (BR) Brazil: Aldoless | Aldomet | Aldotensin | Aldotil | Angimet | Cardiodopa | Dimipress | Dometil | Dopametil | Ductomet | Etildopanan | Furp metildopa | Gendomet | Kindomet | Lfm metildopa | Medpress | Metilcord | Metildopa | Metilpress | Metilprod | Metilvita | Pressomet | Tensioval | Tildomet | Venopressin;
  • (CH) Switzerland: Aldomet;
  • (CI) Côte d'Ivoire: Aldomet | Apo-methyldopa | Dopanore;
  • (CL) Chile: Metildopa;
  • (CO) Colombia: Aldomet | Alfametildopa | Metildopa;
  • (CZ) Czech Republic: Aldomet | Dopagen | Dopamet | Dopegyt;
  • (DE) Germany: Dopegyt | Methyldopa stada | Presinol | Sembrina;
  • (DO) Dominican Republic: Aldomet | Coradopa | Dopabrit | Metildopa | Metildopa ethical;
  • (EC) Ecuador: Aldomet | Metildopa;
  • (EE) Estonia: Aldomet | Dopegyt;
  • (EG) Egypt: Aldomet | Alfadopa | Epidopa | Farcodopa | Kadomet | Medopa;
  • (ES) Spain: Aldomet;
  • (ET) Ethiopia: Asdopa;
  • (FI) Finland: Adopal | Aldomet | Dopamet | Levomet | Medopal | Medopasal | Sembrina;
  • (FR) France: Aldomet | Methyldopa MSD | Methyldopa RPG;
  • (GB) United Kingdom: Aldomet | Dopamet | Hypolar | Lederdopa | Medomet | Metalpha | Methyldopa berk | Methyldopa cox | Methyldopa dc | Methyldopa kent | Methyldopa sandoz | Methyldopa sussex;
  • (GR) Greece: Aldomet | Dopatens | Dopegyt;
  • (HK) Hong Kong: Aldomet | Aldopa | Apo-methyldopa | Dopatab M | Dopegyt | Hydopa | Metopa;
  • (HU) Hungary: Dopegyt;
  • (ID) Indonesia: Aldomet | Aldomet M | Dopamet | Medopa | Tensipas;
  • (IE) Ireland: Aldomet | Meldopa;
  • (IL) Israel: Aldomin;
  • (IN) India: Alphadopa | Alphapress | Emdopa | Gynapres | Medopress;
  • (IT) Italy: Aldomet | Medopren;
  • (JO) Jordan: Aldomet | Dopanore | Dopegyt | Medoram;
  • (JP) Japan: Aldomet | Becanta | Dansul nippon yakko | Dattoryl | Decabolamin | Des tens | Eldopane shionogi | Eldopane takata | Grospisk | Halfdopa | Ledopan | Medoba | Meprin | Methoplain | Methyldopa nichiiko | Methyldopa s.s. seiyaku | Methyldopa sawai | Methyldopa schering | Methyldopa showa | Methyldopa towa | Methyldopa tsuruhara | Polinal | Saipless l | Sankaira yoshindo | Taiadopan | Tildopan | U press dopa;
  • (KE) Kenya: Aldomet | Biodopa | Dawadopa | Medopasel | Neldomet;
  • (KR) Korea, Republic of: L-domex;
  • (KW) Kuwait: Aldomet;
  • (LB) Lebanon: Aldomet;
  • (LT) Lithuania: Aldomet | Dopegyt;
  • (LU) Luxembourg: Aldomet;
  • (LV) Latvia: Aldomet | Dopegyt;
  • (MA) Morocco: Aldomet | Aldopa;
  • (MX) Mexico: Aldomet | Hipermessel | Metildopa | Prodop | Toparal;
  • (MY) Malaysia: Dopamet | Dopatab M | Dopegyt | Medopa | Scandopa;
  • (NG) Nigeria: Aldocure | Aldomet | Aldoxi | Alpadopar | Alphamet | Bioraj methyldopa | Caldopa | Derm methyldopa | Dopaflash | Dopatab | Ketha | Kuka methyldopa | Kuric | N & n methyldopa | Nelb methyldopa | Sunshine coopharm methyldopa | Timeldopa | Vamadopa;
  • (NL) Netherlands: Aldomet | Methyldopa cf;
  • (NO) Norway: Aldomet | Dopamet | Methyldopa cf;
  • (NZ) New Zealand: Methyldopa mylan | Prodopa;
  • (PE) Peru: Aldomet | Dopasan | Metildopa | Metildopamek | Tensodopa;
  • (PH) Philippines: Aldomet | Domepa | Dopamet | Doparine | Dopetens | Meldopa | Ul methyldopa;
  • (PK) Pakistan: Aldomet | M Dopa;
  • (PL) Poland: Aldomet | Dopanol | Dopegyt;
  • (PR) Puerto Rico: Aldomet;
  • (PT) Portugal: Aldomet | Metildopa;
  • (PY) Paraguay: Aditol | Aldopa | Alfametildopa avanova | Alfametildopa dallas | Alfametildopa dutriec | Alfametildopa heisecke | Alfametildopa phi | Alfametildopa vivele | Dopa pres;
  • (RO) Romania: Aldomet | Dopegyt;
  • (RU) Russian Federation: Dopegyt;
  • (SA) Saudi Arabia: Aldomet | Apo-methyldopa | Dopanore;
  • (SE) Sweden: Dopamet | Hyperpaxa;
  • (SG) Singapore: Aldomet | Apo-methyldopa | Dopegyt | Medopa;
  • (SI) Slovenia: Dopegyt | Methyldopa stada | Presinol;
  • (SK) Slovakia: Dopegyt;
  • (TH) Thailand: Adomet | Aldomet | Aldomine | Alfamet | Bedomed | Dopamed | Dopamet | Dopasian | Dopegyt | Isomet | Matilda | Medomet | Medopa | Mefpa | Metpata | Nudopa | Servidopa | Siamdopa;
  • (TN) Tunisia: Aldomet | Dopanore | Dopegyt | Equibar | Methyldopa Teriak;
  • (TR) Turkey: Alfamet;
  • (TW) Taiwan: Aldin | Aldomet | Aldomet M | Aldopa | Almedopa | Highprepin | Medopa | Mepa | Metidopa | Nichidopa | Rivapress | Servidopa;
  • (UA) Ukraine: Dopegyt;
  • (UG) Uganda: Asdopa | Dopamet | Hyodopa | Medopress;
  • (UY) Uruguay: Aldomet | Almedop | Metildopa | Metildopa icu-vita;
  • (VE) Venezuela, Bolivarian Republic of: Aldomet | Metildopa | Tremesal;
  • (VN) Viet Nam: Agidopa;
  • (ZA) South Africa: Aldomet | Be-tabs methyldopa | Hy-po-tone | Hypotone | Merck-methyldopa | Rolab-methyldopa;
  • (ZM) Zambia: Hypotone;
  • (ZW) Zimbabwe: Dopatab M250 | Hypotens | Hypotone | Stridopa
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. American College of Obstetricians and Gynecologists (ACOG). Practice bulletin no. 203: chronic hypertension in pregnancy. Obstet Gynecol. 2019;133(1):e26-e50. [PubMed 30575676]
  3. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. [PubMed 27060684]
  4. Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007.
  5. Arze RS, Ramos JM, Rashid HU, Kerr DN. Amenorrhoea, galactorrhoea, and hyperprolactinaemia induced by methyldopa. Br Med J (Clin Res Ed). 1981;283(6285):194. doi:10.1136/bmj.283.6285.194 [PubMed 6789964]
  6. Bauernfeind R, Hall C, Denes P, Rosen KM. Carotid sinus hypersensitivity with alpha methyldopa. Ann Intern Med. 1978;88(2):214-215. doi:10.7326/0003-4819-88-2-214 [PubMed 626453]
  7. Böttiger LE, Westerholm B. Drug-induced blood dyscrasias in Sweden. Br Med J. 1973;3(5875):339-343. doi:10.1136/bmj.3.5875.339 [PubMed 4723818]
  8. Caldwell JR, Metts JC Jr. Long-term treatment of hypertension with methyldopa. III. Tolerability. J Cardiovasc Pharmacol. 1981;3 Suppl 2:S92-S98. [PubMed 6172672]
  9. Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082 [PubMed 31841131]
  10. Dupont A, Six R. Lupus-like syndrome induced by methyldopa. Br Med J (Clin Res Ed). 1982;285(6343):693-694. doi:10.1136/bmj.285.6343.693-a [PubMed 6809193]
  11. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061. [PubMed 26934393]
  12. Gidseg G. Methyldopa-induced skin rash. South Med J. 1986;79(3):389. doi:10.1097/00007611-198603000-00038 [PubMed 2937156]
  13. Greene R, Spence AW. Neutropenia caused by methyldopa. Br Med J. 1967;4(5579):618. doi:10.1136/bmj.4.5579.618 [PubMed 6060131]
  14. Harth M. L.E. cells and positive direct Coombs' test induced by methyldopa. Can Med Assoc J. 1968;99(6):277-280. [PubMed 4174403]
  15. Hauser GJ, Almog S, Tirosh M, Spirer Z. Effect of alpha-methyldopa excreted in human milk on the breast-fed infant. Helv Paediatr Acta. 1985;40(1):83-86. [PubMed 3843238]
  16. Hoffbrand BI, Fry W, Bunton GL. Cholestatic jaundice due to methyldopa. Br Med J. 1974;3(5930):559. doi:10.1136/bmj.3.5930.559 [PubMed 4412424]
  17. Holt PJ, Navaratnam A. Lichenoid eruption due to methyldopa. Br Med J. 1974;3(5925):234. doi:10.1136/bmj.3.5925.234 [PubMed 4276925]
  18. Kumar KL, Reuler JB. Drug fever. West J Med. 1986;144(6):753-755. [PubMed 3487884]
  19. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. [PubMed 10891521]
  20. Jones HM and Cummings AJ, "A Study of the Transfer of Alpha-Methyldopa to the Human Foetus and Newborn Infant," Br J Clin Pharmacol, 1978, 6(5):432-4. [PubMed 728288]
  21. Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. J Obstet Gynaecol Can. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002 [PubMed 35577426]
  22. Matteson EL, Palella TD. Alpha-methyldopa-induced systemic vasculitis confused with Wegener's granulomatosis. Arthritis Rheum. 1989;32(3):356-357. doi:10.1002/anr.1780320322 [PubMed 2930607]
  23. Methyldopa tablet [prescribing information]. Congers, NY: Chartwell RX; November 2022.
  24. Miller RD, Miller’s Anesthesia, 7th ed, Philadelphia PA: Churchill Livingstone, 2010.
  25. Miller RD, Way WL, and Eger EI. The effects of alpha-methyldopa, reserpine, guanethidine, and iproniazid on minimum alveolar anesthetic requirement (MAC). Anesthesiology. 1968; 29(6):1153-1158. [PubMed 5726752]
  26. Myhre E, Rugstad HE, and Hansen T, “Clinical Pharmacokinetics of Methyldopa,” ClinPharmacokinet, 1982, 7(3):221-33. [PubMed 7047042]
  27. National Heart, Lung, and Blood Institute (NHLBI). Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl 5):S213-S256. [PubMed 22084329]
  28. National Institute for Health and Care Excellence (NICE) guideline. Hypertension in pregnancy: diagnosis and management. http://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.
  29. Neil EM, Waters AK. Generalized choreiform movements as a complication of methyldopa therapy in chronic renal failure. Postgrad Med J. 1981;57(673):732-733. doi:10.1136/pgmj.57.673.732 [PubMed 7339611]
  30. Newman RJ, Salerno HR. Letter: sexual dysfunction due to methyldopa. Br Med J. 1974;4(5936):106. doi:10.1136/bmj.4.5936.106-b [PubMed 4414389]
  31. Park, MK. Park's Pediatric Cardiology for Practitioners. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.
  32. Paykel ES, Fleminger R, Watson JP. Psychiatric side effects of antihypertensive drugs other than reserpine. J Clin Psychopharmacol. 1982;2(1):14-39. doi:10.1097/00004714-198202000-00004 [PubMed 6121825]
  33. Pettinger WA, Horwitz D, Sjoerdsma A. Lactation due to methyldopa. Br Med J. 1963;1(5343):1460. doi:10.1136/bmj.1.5343.1460 [PubMed 13942986]
  34. Redman CW. Hypertension in pregnancy: the NICE guidelines. Heart. 2011;97(23):1967-1969. [PubMed 21990386]
  35. Refer to manufacturer's labeling.
  36. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-3241. [PubMed 30165544]
  37. Shashaty GG. Cryptogenic cirrhosis associated with methyldopa. South Med J. 1979;72(3):364-366. doi:10.1097/00007611-197903000-00040 [PubMed 424836]
  38. Skerjanec A, Campbell NR, Robertson S, et al, “Pharmacokinetics and Presystemic Gut Metabolism of Methyldopa in Healthy Human Subjects,” J Clin Pharmacol, 1995, 35(3):275-80. [PubMed 7608316]
  39. Strang RR. Parkinsonism occurring during methyldopa therapy. Can Med Assoc J. 1966;95(18):928-929. [PubMed 5921753]
  40. Surveyor I, Evans B, Saunders KC, Parry TE. Autoimmune haemolytic anaemic complicating methyldopa therapy. Postgrad Med J. 1968;44(512):438-442. doi:10.1136/pgmj.44.512.438 [PubMed 5665742]
  41. Thomas LA, Cardwell MS. Acute reactive hepatitis in pregnancy induced by alpha-methyldopa. Obstet Gynecol. 1997;90(4 Pt 2):658-659. doi:10.1016/s0029-7844(97)00239-1 [PubMed 11770583]
  42. Toghill PJ, Smith PG, Benton P, Brown RC, Matthews HL. Methyldopa liver damage. Br Med J. 1974;3(5930):545-548. doi:10.1136/bmj.3.5930.545 [PubMed 4414663]
  43. Van der Heide H, Ten Haaft MA, Stricker BH. Pancreatitis caused by methyldopa. Br Med J (Clin Res Ed). 1981;282(6280):1930-1931. doi:10.1136/bmj.282.6280.1930 [PubMed 6786677]
  44. Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol. 1996;27 Suppl 3:S49-S54. doi:10.1097/00005344-199627003-00007 [PubMed 8872299]
  45. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065 [PubMed 29133356]
  46. White WB, Andreoli JW, and Cohn RD, "Alpha-Methyldopa Disposition in Mothers With Hypertension and in Their Breast-Fed Infants," Clin Pharmacol Ther, 1985, 37(4):387-90. [PubMed 3838502]
  47. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435
  48. Yeh BK, Dayton PG, and Waters WC 3rd. Removal of alpha-methyldopa (aldomet) in man by dialysis. Proc Soc Exp Biol Med. 1970;135(3):840-843. [PubMed 5486722]
Topic 9635 Version 294.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟